« Back
Home /
Dabrafenib

Dabrafenib

Item no.	HY-14660-1g
Manufacturer	MedChem Express
CASRN	1195765-45-7
Amount	1 g
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 200 mg 500 mg 50 mg 5 mg
Category	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920.\|[2]Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22.\|[3]Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.\|[4]Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405.\|[5]Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52. ACS Comb Sci. 2019 Dec 9;21(12):805-816.\|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Adv Sci (Weinh). 2024 Jun 3:e2400023.\|Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489.\|Biochem Biophys Res Commun. 2020 Feb 5;522(2):395-401. \|Biomed Pharmacother. 2024 Jun 27:177:117033.\|Biophys J. 2018 Mar 27;114(6):1499-1511. \|bioRxiv. 2019 Oct 28.\|bioRxiv. 2019 Oct. \|bioRxiv. 2019 Sep.\|bioRxiv. 2024 August 16.\|bioRxiv. 2024 Dec 20:2024.12.19.629301.\|Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8.\|Cancer Cell. 2024 Mar 11;42(3):358-377.e8.\|Cancer Res Commun. 2024 Aug 30.\|Cell Biochem Biophys. 2024 Sep 24.\|Cell Death Differ. 2022 Jan 22.\|Cell Metab. 2025 Feb 28:S1550-4131(25)00021-X.\|Cell Mol Gastroenterol Hepatol. 2021 Oct 23;S2352-345X(21)00223-X.\|Cell Rep Med. 2023 Jan 10;100911.\|Cell Rep Med. 2024 Mar 19;5(3):101471.\|Cell Res. 2025 Jan 2.\|Cell Syst. 2020 Nov 18;11(5):478-494.e9.\|Cell. 2024 Jan 4;187(1):166-183.e25.\|Cell. 2018 Aug 9;174(4):843-855.e19.\|Cells. 2019 Dec 6;8(12):1582.\|Elife. 2020 Dec 7;9:e61405.\|Endocrine. 2024 Aug 13.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Harvard Medical School LINCS LIBRARY\|Int J Cancer. 2019 Mar 15;144(6):1379-1390.\|Int J Mol Sci. 2022 Nov 19;23(22):14385.\|J Cell Mol Med. 2020 Mar;24(6):3336-3345.\|J Control Release. 2024 Sep 23:375:643-653.\|J Pers Med. 2022, 12(1), 77.\|J Transl Med. 2023 Jan 9;21(1):9.\|JCO Precis Oncol. 2024 Apr:8:e2300538.\|Mol Cell. 2019 Jan 3;73(1):7-21.e7. \|Mol Ther Nucleic Acids. 2024 Jul 19;35(3):102283.\|Mol Ther Oncolytics. 2019 Feb 5;12:235-245.\|Mol Ther Oncolytics. 2019 Feb 5;12:235-245.\|Nat Biomed Eng. 2018 Aug;2(8):578-588.\|Oncotarget. 2017 Apr 4;8(14):23436-23447. \|Patent. US20240366605A1.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Redox Biol. October 2021, 102110.\|Research Square Preprint. 2023 May 5.\|Sci Data. 2024 Sep 19.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Science. 2017 Dec 1;358(6367):eaan4368.\|Toxicol Appl Pharmacol. 2021 Nov 12;115797.\|Toxicol In Vitro. 2020 Jun;65:104777.\|Toxicology. 2024 Apr 17:153807.\|bioRxiv. 2023 Nov 13.\|Cancer Cell. 2020 Mar 16;37(3):387-402.e7. \|Cancer Res. 2022 May 18;canres.4152.2021.\|J Am Soc Nephrol. 2023 Nov 14.\|JCI Insight. 2023 Nov 7:e171140.\|Patent. US20240307400A1.\|Patent. US20240366605A1
Smiles	CC(C)(C)C1=NC(C2=C(F)C(NS(C3=C(F)C=CC=C3F)(=O)=O)=CC=C2)=C(C4=CC=NC(N)=N4)S1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK2118436A,GSK2118436
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Raf
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	519.56
Product Description	Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 33 mg/mL
Manufacturer - Pathway	MAPK/ERK Pathway
Isoform	B-Raf; C-Raf
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14660-1g-safety-datasheet.pdf